Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ACP-105 and RAD-140 — mechanism, side effects, legal status, and pricing.
ACP-105 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) of the azabicyclooctane chemotype, structurally related to AC-262536 and RAD140. It acts as a partial agonist at the androgen receptor with tissue-selective anabolic effects demonstrated in preclinical models. ACP-105 is not an approved drug in any jurisdiction and has never entered human clinical trials. SARMs as a class are prohibited at all times under WADA Prohibited List S1.2 'Other Anabolic Agents'; ACP-105 falls under this class-wide ban and has been the subject of equine anti-doping metabolite-detection research.
RAD-140 (testolone) is a non-steroidal small-molecule selective androgen receptor modulator (SARM) — not a peptide — developed by Radius Health. It is NOT FDA-approved for any indication. Grey-market use for bodybuilding is associated with documented drug-induced liver injury (hepatotoxicity), testosterone suppression, and adverse cardiovascular effects. It is a WADA-prohibited substance. It is tracked in peptide-research spaces because of overlapping grey-market performance use.
ACP-105
RAD-140
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ACP-105
RAD-140
No pricing data yet.
Check RAD-140 prices →COA corpus from Disclosed Labs — independently tested batches only.
ACP-105
2
COAs
99.3%
Avg purity
1
Labs
RAD-140
No COA data yet.
Submit testing data →No human data exist for ACP-105. In castrated male rats, 2-week oral dosing improved anabolic parameters consistent with tissue-selective partial AR agonism, suppressed the LH surge, and produced levator ani muscle anabolic effects. In female mice (whole-body irradiated and sham-irradiated), ACP-105 preserved rotorod sensorimotor performance impaired by radiation and enhanced cued fear conditioning while reducing MAP-2 immunoreactivity in sensorimotor cortex. In male gonadectomized 3xTg-AD Alzheimer's-model mice, ACP-105 alone reduced anxiety-like behavior; combined with the ER-beta agonist AC-186, it improved cognition (Morris water maze), increased amyloid-beta-degrading enzymes (neprilysin, IDE), and decreased brain amyloid-beta versus vehicle. Equine in vitro liver microsome studies identified twelve Phase I metabolites for doping-control detection purposes.
Key references
Miller et al. (2010, ACS Med Chem Lett) first described the design, synthesis, and preclinical characterization of RAD140 as a high-affinity tissue-selective AR agonist. Jayaraman et al. (2014, Endocrinology) demonstrated neuroprotection in cultured neurons and kainate-lesioned rats. LoRusso et al. (2022, Clinical Breast Cancer) reported the first-in-human Phase 1 dose-escalation in ER+/HER2- metastatic breast cancer (MTD 100 mg/day); efficacy was modest and hepatic AEs were frequent (AST 59%, ALT 46%, bilirubin 27%), and development did not progress to approval. Leung et al. (2022, Ochsner Journal) and subsequent case series document severe cholestatic drug-induced liver injury from grey-market RAD-140 use. Van Wagoner et al. (2017, JAMA) showed that only ~52% of internet-marketed SARM products contained the labeled compound, compounding grey-market risk. FDA has issued public warnings that SARMs are not safe for human consumption, and RAD-140 is banned by WADA. No FDA approval pathway is currently established.
ACP-105 and RAD-140 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs